Related Experiment Video
Updated: Oct 23, 2025

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
Structural features of Cryptococcus neoformans bifunctional GAR/AIR synthetase may present novel antifungal drug
Sheena M H Chua1, Maha S I Wizrah1, Zhenyao Luo2
1Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, Queensland, Australia; School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Abstract:
Cryptococcus neoformans is a fungus that causes life-threatening systemic mycoses. During infection of the human host, this pathogen experiences a major change in the availability of purines; the fungus can scavenge the abundant purines in its environmental niche of pigeon excrement, but must employ de novo biosynthesis in the purine-poor human CNS. Eleven sequential enzymatic steps are required to form the first purine base, IMP, an intermediate in the formation of ATP and GTP. Over the course of evolution, several gene fusion events led to the formation of multifunctional purine biosynthetic enzymes in most organisms, particularly the higher eukaryotes. In C. neoformans, phosphoribosyl-glycinamide synthetase (GARs) and phosphoribosyl-aminoimidazole synthetase (AIRs) are fused into a bifunctional enzyme, while the human ortholog is a trifunctional enzyme that also includes GAR transformylase. Here we functionally, biochemically, and structurally characterized C. neoformans GARs and AIRs to identify drug targetable features. GARs/AIRs are essential for de novo purine production and virulence in a murine inhalation infection model. Characterization of GARs enzymatic functional parameters showed that C. neoformans GARs/AIRs have lower affinity for substrates glycine and PRA compared with the trifunctional metazoan enzyme. The crystal structure of C. neoformans GARs revealed differences in the glycine- and ATP-binding sites compared with the Homo sapiens enzyme, while the crystal structure of AIRs shows high structural similarity compared with its H. sapiens ortholog as a monomer but differences as a dimer. The alterations in functional and structural characteristics between fungal and human enzymes could potentially be exploited for antifungal development.
Insights
Cryptococcus neoformans purine biosynthesis enzymes GARs/AIRs are essential for fungal virulence. Differences in their structure and function compared to human enzymes offer potential antifungal drug targets.
Area of Science:
- Medical Mycology
- Biochemistry
- Structural Biology
Background:
- * Cryptococcus neoformans causes life-threatening fungal infections.
- * Pathogen adapts to purine availability changes, relying on de novo purine biosynthesis in the human central nervous system (CNS).
- * Purine biosynthesis involves 11 enzymatic steps, with gene fusions creating multifunctional enzymes in eukaryotes.
Purpose of the Study:
- * To functionally, biochemically, and structurally characterize Cryptococcus neoformans GARs/AIRs.
- * To identify drug-targetable features of these essential fungal enzymes.
- * To understand evolutionary differences in purine biosynthesis enzymes between fungi and humans.
Main Methods:
- * Functional characterization of C. neoformans GARs/AIRs.
- * Biochemical assays to determine enzyme kinetic parameters.
- * X-ray crystallography to determine the structures of C. neoformans GARs and AIRs.
- * Virulence assessment in a murine inhalation infection model.
Main Results:
- * C. neoformans GARs/AIRs are essential for de novo purine production and virulence.
- * C. neoformans GARs/AIRs exhibit lower substrate affinity (glycine, PRA) than the human trifunctional enzyme.
- * Structural analysis revealed distinct substrate-binding sites in C. neoformans GARs and differences in AIRs dimerization compared to human orthologs.
Conclusions:
- * C. neoformans GARs/AIRs are crucial for fungal survival and pathogenesis.
- * Functional and structural disparities between fungal and human enzymes present opportunities for targeted antifungal drug development.
- * Exploiting these differences could lead to novel therapies against C. neoformans infections.
More Related Videos
Related Concept Videos
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Fungal Group Zygomycota

